Citizens Raises Benitec Biopharma's Price Target to $22 Amid Positive Oculopharyngeal Muscular Dystrophy Treatment Results

Citizens JMP raised Benitec Biopharma Inc.'s (BNTC) price target to $22 from $20, citing positive topline clinical data results for its treatment of Oculopharyngeal Muscular Dystrophy (OPMD). The treatment achieved a 100% response rate in Phase 1b/2a trials, reducing swallowing difficulties and shortening liquid consumption time. The FDA has granted the treatment Fast Track designation. Suvretta Capital Management also invested $20 million in the company.